February 22, 2022
Professor William Hwang is the Medical Director of the National Cancer Centre of Singapore (NCCS), Chair of the Oncology Academic Clinical Programme (ACP) in the SingHealth Duke-NUS Academic Medical Centre, Head of the SingHealth Duke-NUS Cell Therapy Centre, and one of the research faculty in the Duke-NUS Cancer and Stem Cell Biology (CSCB) programme. He is serving as Chairman, Biobanking Advisory, Ministry of Health (MOH); Co-Chair, National Advisory Committee on Cancer Care (NACC), MOH; Co-Chair, Cell, Tissue and Gene Therapy (CTGT) Regulations workgroup, MOH; Member, Hematopoietic Stem Cell Transplant Regulations workgroup, MOH. He is also Board Organising Committee (BOC) member of the Singapore Translational Cancer Consortium.
He has previously served as Medical Director of the Singapore Cord Blood Bank, Head for the Department of Haematology in the Singapore General Hospital and Head of the SingHealth Duke-NUS Blood Cancer Centre as well as Director for SingHealth Transplant.
He was previously President of the World Marrow Donor Association (WMDA), and Advisory Board member of the Centre for International Blood and Marrow Transplant Research (CIBMTR, based in the USA). He served as Congress President for the 2016 Asia Pacific Blood and Marrow Transplant Group (APBMT) meeting and currently serves as Executive Board member of the APBMT.
Prof Hwang has published over 120 papers in medicine and science, particularly in the field of haematology and HSC.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system